Exploring the prognostic value of the magnesium-immune prognostic score (MIPS) in metastatic non-small cell lung cancer receiving Nivolumab.
2/5 보강
TL;DR
The MIPS represents a simple, accessible, and clinically applicable prognostic and predictive tool for stratifying metastatic NSCLC patients receiving nivolumab by integrating inflammatory, nutritional, and metabolic components, and offers a holistic assessment of patient biology.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
95 patients with advanced NSCLC treated with nivolumab.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
By integrating inflammatory, nutritional, and metabolic components, the score offers a holistic assessment of patient biology. Prospective validation studies are warranted.
OpenAlex 토픽 ·
Biomarkers in Disease Mechanisms
Magnesium in Health and Disease
Cancer Immunotherapy and Biomarkers
The MIPS represents a simple, accessible, and clinically applicable prognostic and predictive tool for stratifying metastatic NSCLC patients receiving nivolumab by integrating inflammatory, nutritiona
- p-value p < 0.001
- HR 2.694
APA
Sait Kitaplı, Melih Akpunar, et al. (2026). Exploring the prognostic value of the magnesium-immune prognostic score (MIPS) in metastatic non-small cell lung cancer receiving Nivolumab.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 28(5), 1691-1707. https://doi.org/10.1007/s12094-025-04147-x
MLA
Sait Kitaplı, et al.. "Exploring the prognostic value of the magnesium-immune prognostic score (MIPS) in metastatic non-small cell lung cancer receiving Nivolumab.." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 28, no. 5, 2026, pp. 1691-1707.
PMID
41307867
Abstract
[BACKGROUND] Although immune checkpoint inhibitors have transformed the treatment landscape in advanced non-small cell lung cancer (NSCLC), reliable and accessible biomarkers to predict survival and treatment response remain limited. This study aimed to evaluate the prognostic and predictive utility of the Magnesium-Immune Prognostic Score (MIPS), a composite index based on neutrophil-to-lymphocyte ratio and serum levels of C-reactive protein, magnesium, albumin, calcium, phosphorus, lactate dehydrogenase, and uric acid, in metastatic NSCLC patients receiving second-line nivolumab.
[METHODS] This retrospective study included 95 patients with advanced NSCLC treated with nivolumab. The MIPS was constructed by integrating three predefined component indices: the Inflammation-Mediated Immunity Index (IMI), the Mineral and Nutritional Index (MINI), and the Aggressive Tumor Index (ATI). Survival outcomes were analyzed using ROC curves, Kaplan-Meier methods, and Cox regression models.
[RESULTS] Among 95 patients, those with high MIPS had significantly shorter progression-free survival and overall survival than those with low MIPS (p < 0.001). In multivariable Cox analysis, high MIPS remained an independent predictor of poor OS (HR: 2.694, p < 0.001). Among all indices, MIPS showed the strongest discriminative ability (AUC = 0.696). All four composite indices-IMI, MINI, ATI, and MIPS-were significantly associated with treatment response, with high-score groups demonstrating higher rates of good response (CR + PR), and MIPS showing the strongest association (p < 0.001).
[CONCLUSION] The MIPS represents a simple, accessible, and clinically applicable prognostic and predictive tool for stratifying metastatic NSCLC patients receiving nivolumab. By integrating inflammatory, nutritional, and metabolic components, the score offers a holistic assessment of patient biology. Prospective validation studies are warranted.
[METHODS] This retrospective study included 95 patients with advanced NSCLC treated with nivolumab. The MIPS was constructed by integrating three predefined component indices: the Inflammation-Mediated Immunity Index (IMI), the Mineral and Nutritional Index (MINI), and the Aggressive Tumor Index (ATI). Survival outcomes were analyzed using ROC curves, Kaplan-Meier methods, and Cox regression models.
[RESULTS] Among 95 patients, those with high MIPS had significantly shorter progression-free survival and overall survival than those with low MIPS (p < 0.001). In multivariable Cox analysis, high MIPS remained an independent predictor of poor OS (HR: 2.694, p < 0.001). Among all indices, MIPS showed the strongest discriminative ability (AUC = 0.696). All four composite indices-IMI, MINI, ATI, and MIPS-were significantly associated with treatment response, with high-score groups demonstrating higher rates of good response (CR + PR), and MIPS showing the strongest association (p < 0.001).
[CONCLUSION] The MIPS represents a simple, accessible, and clinically applicable prognostic and predictive tool for stratifying metastatic NSCLC patients receiving nivolumab. By integrating inflammatory, nutritional, and metabolic components, the score offers a holistic assessment of patient biology. Prospective validation studies are warranted.
MeSH Terms
Humans; Nivolumab; Carcinoma, Non-Small-Cell Lung; Male; Female; Lung Neoplasms; Retrospective Studies; Middle Aged; Prognosis; Aged; Magnesium; Neutrophils; Adult; C-Reactive Protein; Biomarkers, Tumor; Immune Checkpoint Inhibitors; Lymphocytes; Aged, 80 and over; Progression-Free Survival; Antineoplastic Agents, Immunological